Could canakinumab be used for COVID-19?
https://doi.org/10.37489/2588-0519-2020-S4-50-52
Abstract
Use of canakinumab in patients with COVID-19 is currently lacking proper evidence base, and should not be recommended outside of clinical trials.
About the Authors
V. A. Otdelenov
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770
Moscow
K. B. Mirzaev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. State register of medicines. Canakinumab (Ilaris). Instructions for medical use. (In Russ). Доступно по: https://clck.ru/REWdq Ссылка активна на 19.05.2020.
2. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. DOI: 10.1007/s00281-017-0629-x
3. Wong CK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004 Apr;136(1):95-103. DOI: 10.1111/j.1365-2249.2004.02415.x
4. Gong J et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. MedRxiv. 2020 February 27. DOI: 10.1101/2020.02.25.20025643
5. Temporary guidelines of the Ministry of health of the Russian Federation for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 6 (28.04.2020). (In Russ). Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_МR_COVID-19_v6.pdf Ссылка активна на 19.05.20206.
6. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. [cited 2020 May 19]; Available from: https://www.covid19treatmentguidelines.nih.gov/
7. UW Medicine COVID-19 Resource Site [Internet]. University of Washington. 2020. [cited 2020 May 16]; Available from: https://covid-19.uwmedicine.org/Pages/default.aspx
8. Brigham and Women’s Hospital COVID-19 Clinical Guidelines. Therapeutics. Anti-IL-1 Agents (Anakinra, Canakinumab, Rilonacept). [Internet]. [cited 2020 May 22]; Available from: https://clck.ru/REWeU
9. Search of: canakinumab | COVID-19. List Results. ClinicalTrials.gov. [Internet]. [cited 2020 May 19]; Available from: https://clck.ru/REWfu
10. Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19. Full Text View. ClinicalTrials.gov. [Internet]. [cited 2020 May 19]; Available from: https://clinicaltrials.gov/ct2/show/NCT04365153
11. Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia. Full Text View. ClinicalTrials.gov. [Internet]. [cited 2020 May 19]; Available from: https://clinicaltrials.gov/ct2/show/NCT04362813
12. Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia. Full Text View. ClinicalTrials.gov. [Internet]. [cited 2020 May 20]; Available from: https://clinicaltrials.gov/ct2/show/NCT04348448
13. ILARIS (canakinumab). FULL PRESCRIBING INFORMATION [Internet]. [cited 2020 May 20]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf
Review
For citations:
Otdelenov V.A., Mirzaev K.B., Sychev D.A. Could canakinumab be used for COVID-19? Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):50-52. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-50-52
Views:
1651
Email this article 